Trial Profile
Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65,Adopting Randomized Blinded and Parallel Controlled Method
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mycobacterium riyadhense (Primary)
- Indications Tuberculosis
- Focus Diagnostic use
- Sponsors AnHui Longcom Biologic Pharmacy
- 22 May 2021 Results from two clinical studies (NCT02336542 and NCT02389322) published in the Clinical Infectious Diseases
- 08 Dec 2015 New trial record